Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Gains U.S. Diabetes Indication For Cholesterol Drug WelChol

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo received U.S. FDA sNDA approval for its cholesterol drug WelChol (colesevelam) as an adjunct therapy to improve glycemic control in patients with type 2 diabetes Jan. 18

You may also be interested in...



Daiichi Sankyo U.S. CEO Joe Pieroni: An Interview With "The Pink Sheet" DAILY (Part 1 of 2)

Daiichi Sankyo's head of U.S. operations Joe Pieroni sat down with "The Pink Sheet" DAILY recently at the firm's U.S. headquarters in Parsippany, N.J., to discuss the company's cardiovascular products and pipeline and how the Japanese pharma is looking to the U.S. market as a core growth driver. Pieroni was tapped to lead the newly formed U.S. subsidiary in 2005 following the merger of Daiichi and Sankyo. Previously, Mr. Pieroni had launched Sankyo's U.S. commercial operations, first as president of the Sankyo Parke-Davis joint venture and then as president of Sankyo Pharma Inc., a wholly owned U.S. subsidiary.

Daiichi Sankyo Submits WelChol sNDA For Diabetes Indication

If approved, WelChol would be the first LDL-lowering therapy also approved for improving glycemic control.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel